2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations

Treatment of hypertension improves cardiovascular, renal, and cerebrovascular outcomes. However, the benefit of treatment may be different according to the patients’ characteristics. Additionally, the target blood pressure or initial drug choice should be customized according to the special conditions of the hypertensive patients. In this part III, we reviewed previous data and presented recommendations for some special populations such as diabetes mellitus, chronic kidney disease, elderly people, and cardio-cerebrovascular disease.

[1]  E. Ross,et al.  Philosophy of Science Association , 2022 .

[2]  K. Radack,et al.  Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. , 1991, Archives of internal medicine.

[3]  S. Nattel,et al.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. , 1991, Circulation.

[4]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[5]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[6]  W. Applegate,et al.  Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. , 1994, Archives of internal medicine.

[7]  Daniel W. Jones,et al.  Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey , 1994, Journal of hypertension.

[8]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[9]  Pats,et al.  Post-stroke antihypertensive treatment study. A preliminary result. , 1995, Chinese medical journal.

[10]  Pats-Collaborating-Group-.  Post-stroke antihypertensive treatment study. A preliminary result , 1995 .

[11]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[12]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[13]  L. Fried,et al.  Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. , 1996, Stroke.

[14]  J. Manson,et al.  Prospective study of oral contraceptives and hypertension among women in the United States. , 1996, Circulation.

[15]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[16]  J F Toole,et al.  Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1996, Stroke.

[17]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[18]  F. Locatelli,et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.

[19]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[20]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[21]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[22]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[23]  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) , 1997, Lancet.

[24]  T. N. t-P. S. S. Group,et al.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. , 1997, Stroke.

[25]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[26]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[27]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[28]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[29]  J. Staessen,et al.  The epidemiology of the association between hypertension and menopause , 1998, Journal of Human Hypertension.

[30]  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[31]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[32]  A. Bignamini,et al.  Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. , 1999, American journal of hypertension.

[33]  D. Bliwise,et al.  Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. , 1999, Critical care medicine.

[34]  G. Remuzzi,et al.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. , 1999, Journal of the American Society of Nephrology : JASN.

[35]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[36]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[37]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[38]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[39]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[40]  C. Schmid,et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.

[41]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[42]  J. Blacher,et al.  Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure , 2001, Circulation.

[43]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[44]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[45]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[46]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[47]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[48]  M. Weir,et al.  The β Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions? , 2001, Journal of clinical hypertension.

[49]  D. Beevers,et al.  Clinical Hypertension , 2002, Journal of Human Hypertension.

[50]  N. Hollenberg,et al.  Literature alert , 2002 .

[51]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[52]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[53]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[54]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[55]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[56]  L. Prisant.  Challenges for beta-blockers as first-line therapy for elderly hypertensive patients. , 2002, Postgraduate medicine.

[57]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[58]  Jiang He,et al.  Effect of Aerobic Exercise on Blood Pressure , 2002, Annals of Internal Medicine.

[59]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[60]  J. Sowers,et al.  Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. , 2002, Hypertension.

[61]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[62]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[63]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[64]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[65]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[66]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[67]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[68]  J. Leonardi-Bee,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.

[69]  Peter W de Leeuw,et al.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.

[70]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[71]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[72]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[73]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[74]  Daniel W. Jones,et al.  Seventh report of the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): Resetting the hypertension sails , 2003 .

[75]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[76]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[77]  W. Aronow,et al.  Treatment of hypertension and prevention of ischemic stroke , 2004, Current cardiology reports.

[78]  Eiji Yano,et al.  Blood Pressure Management in Acute Intracerebral Hemorrhage: Relationship Between Elevated Blood Pressure and Hematoma Enlargement , 2004, Stroke.

[79]  Anthony Rodgers,et al.  Blood Pressure and Stroke: An Overview of Published Reviews , 2004, Stroke.

[80]  S. Yusuf,et al.  Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease , 2004 .

[81]  G. Mancia,et al.  Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. , 2004, American journal of hypertension.

[82]  J. Reckelhoff,et al.  Novel mechanisms responsible for postmenopausal hypertension. , 2004, Hypertension.

[83]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[84]  G. Mancia,et al.  Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-Blind Trial , 2004, Stroke.

[85]  W. Jagust,et al.  Determinants of vascular dementia in the Cardiovascular Health Cognition Study , 2005, Neurology.

[86]  Michael F O'Rourke,et al.  Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. , 2005, Hypertension.

[87]  A. House,et al.  Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. , 2005, American journal of hypertension.

[88]  J. Manson,et al.  Association between body mass index and CKD in apparently healthy men. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[89]  Yutaka Imai,et al.  Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. , 2005, Journal of the American College of Cardiology.

[90]  J. Schwartz,et al.  Short- and Long-Term Incidence of Stroke in White-Coat Hypertension , 2005, Hypertension.

[91]  Li-sheng Liu,et al.  The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients , 2005, Journal of hypertension.

[92]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[93]  J. Murabito,et al.  Temporal trends in the incidence of intermittent claudication from 1950 to 1999. , 2005, American journal of epidemiology.

[94]  Neil Chapman,et al.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[95]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[96]  G. Remuzzi,et al.  Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial , 2005, The Lancet.

[97]  P. Verdecchia,et al.  The natural history of white-coat hypertension in the long term. , 2005, Blood pressure monitoring.

[98]  J. Laragh,et al.  Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial , 2006, Journal of hypertension.

[99]  M. Woodward,et al.  Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial , 2006, Journal of hypertension.

[100]  G. Moneta.  Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-blind TrialZanchetti A, for the PHYLLIS Investigators (Univ , 2006 .

[101]  M. Yılmaz,et al.  Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients , 2006, Journal of hypertension.

[102]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[103]  C. Wiysonge,et al.  Beta-blockers for hypertension. , 2007, The Cochrane database of systematic reviews.

[104]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[105]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[106]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[107]  C. Lau,et al.  Development of Diabetes in Chinese With the Metabolic Syndrome , 2007, Diabetes Care.

[108]  J. Le Heuzey,et al.  Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. , 2007, European heart journal.

[109]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[110]  A. Tveit,et al.  Candesartan in the prevention of relapsing atrial fibrillation. , 2007, International journal of cardiology.

[111]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[112]  J. Gaziano,et al.  Effect of treating erectile dysfunction on management of systolic hypertension. , 2007, The American journal of cardiology.

[113]  A. Divani,et al.  Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. , 2007, The American journal of emergency medicine.

[114]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[115]  G. Mancia,et al.  Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study , 2007, Hypertension.

[116]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[117]  S. Y. Lee,et al.  Appropriate waist circumference cutoff points for central obesity in Korean adults. , 2007, Diabetes research and clinical practice.

[118]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[119]  M. D. De Buyzere,et al.  Management of hypertension in peripheral arterial disease. , 2008, Progress in cardiovascular diseases.

[120]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[121]  M. Woodward,et al.  Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. , 2008, European heart journal.

[122]  A. Zanchetti,et al.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial , 2008, Journal of hypertension.

[123]  M. Volpe,et al.  Development of heart failure in recent hypertension trials , 2008, Journal of hypertension.

[124]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[125]  G. Viberti,et al.  Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering , 2008, Hypertension.

[126]  김성권,et al.  The Prevalence of Chronic Kidney Disease and the Predictors of Decreased Kidney Function in Hypertensive Patients , 2008 .

[127]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[128]  D. Singer,et al.  Management of hypertension in peripheral arterial disease: does the choice of drugs matter? , 2008, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[129]  S. Lewis,et al.  Alcohol Intake and Blood Pressure: A Systematic Review Implementing a Mendelian Randomization Approach , 2008, PLoS medicine.

[130]  A. Manolis,et al.  Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications , 2008, Journal of hypertension.

[131]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[132]  E. Ferenczi,et al.  Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure , 2008, Heart.

[133]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[134]  S. Yusuf,et al.  Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. , 2008, American heart journal.

[135]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[136]  Chaoyang Li,et al.  Metabolic Syndrome and Incident Diabetes , 2008, Diabetes Care.

[137]  Yasmin,et al.  A comparison of atenolol and nebivolol in isolated systolic hypertension , 2008, Journal of hypertension.

[138]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[139]  Chih-Hsing Wu,et al.  Population-Based Study on the Prevalence and Correlates of Orthostatic Hypotension/Hypertension and Orthostatic Dizziness , 2008, Hypertension Research.

[140]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[141]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[142]  石井當男.  Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) , 2008, Hypertension Research.

[143]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[144]  A. Da Silva,et al.  Beta blockers for peripheral arterial disease. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[145]  T. Ninomiya,et al.  Impact of Metabolic Syndrome Compared With Impaired Fasting Glucose on the Development of Type 2 Diabetes in a General Japanese Population , 2009, Diabetes Care.

[146]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[147]  Li-sheng Liu,et al.  Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature , 2009, Hypertension Research.

[148]  G. Oster,et al.  Excess risk of diabetes in persons with hypertension. , 2009, Journal of diabetes and its complications.

[149]  G. Navis,et al.  Benefits of dietary sodium restriction in the management of chronic kidney disease , 2009, Current opinion in nephrology and hypertension.

[150]  M. Kaste,et al.  Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis: Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) , 2009, Stroke.

[151]  S. Lakhan,et al.  Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis , 2009, International archives of medicine.

[152]  S. Oparil,et al.  Hypertension in the elderly. , 2009, Clinics in geriatric medicine.

[153]  A. Hughes,et al.  Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial , 2009, Diabetologia.

[154]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[155]  F. Rutten,et al.  Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. , 2010, Archives of internal medicine.

[156]  J. Montserrat,et al.  Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. , 2010, American journal of respiratory and critical care medicine.

[157]  P. Lloberes,et al.  Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial , 2010, Journal of hypertension.

[158]  M. Böhm,et al.  Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition , 2010 .

[159]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[160]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[161]  J. Elefteriades,et al.  Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. , 2010, Journal of the American College of Cardiology.

[162]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[163]  W. W. Brabham.  Valsartan for Prevention of Recurrent Atrial Fibrillation , 2010 .

[164]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[165]  S. Denardo,et al.  Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease: Findings From the INternational VErapamil-SR/Trandolapril STudy , 2010, Hypertension.

[166]  A. Braverman.  Acute aortic dissection: clinician update. , 2010, Circulation.

[167]  J. McMurray,et al.  Clinical practice. Systolic heart failure. , 2010, The New England journal of medicine.

[168]  Stéphane Laurent,et al.  Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination: The EXPLOR Study , 2010, Hypertension.

[169]  T. Ogihara,et al.  Comparison of strict- and mild-blood pressure control in elderly hypertensive patients: a per-protocol analysis of JATOS , 2010, Hypertension Research.

[170]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[171]  C. Bulpitt,et al.  Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial , 2010, The Lancet Neurology.

[172]  Mary G. George,et al.  Trends in Pregnancy Hospitalizations That Included a Stroke in the United States From 1994 to 2007: Reasons for Concern? , 2011, Stroke.

[173]  D. Jatužis,et al.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial , 2011, The Lancet.

[174]  S. Laurent,et al.  Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients , 2010, Journal of hypertension.

[175]  M. Murad,et al.  The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. , 2011, Archives of internal medicine.

[176]  C. Kwak,et al.  Prevalence and Associated Risk Factors for Cardiovascular Disease: Findings from the 2005, 2007 Korea National Health and Nutrition Examination Survey , 2011 .

[177]  G. Breithardt,et al.  Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options , 2011, Thrombosis and Haemostasis.

[178]  J. Kals,et al.  Differential Effects of Nebivolol and Metoprolol on Central Aortic Pressure and Left Ventricular Wall Thickness , 2011, Hypertension.

[179]  V. Regitz-Zagrosek.  Sex and gender differences in symptoms of myocardial ischaemia. , 2011, European heart journal.

[180]  T. Douglas Bradley,et al.  Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated With Resistant Hypertension , 2011, Hypertension.

[181]  L. Qin,et al.  Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. , 2011, Journal of the American College of Cardiology.

[182]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[183]  P. Lindsay,et al.  Canadian Hypertension Education Program: the science supporting New 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation. , 2011, The Canadian journal of cardiology.

[184]  M. Pfeffer,et al.  Irbesartan in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[185]  A. Rabinstein.  Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial , 2011 .

[186]  L. Krakoff,et al.  Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. , 2011, American journal of hypertension.

[187]  K. Reynolds,et al.  Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-Analysis , 2012 .

[188]  Sung Hee Choi,et al.  Increasing Prevalence of Metabolic Syndrome in Korea , 2011, Diabetes Care.

[189]  G. Hankey.  Lowering blood pressure in acute stroke: the SCAST trial , 2011, The Lancet.

[190]  J. McMurray,et al.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. , 2012, Journal of the American College of Cardiology.

[191]  I. Chetter,et al.  Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. , 2012, Atherosclerosis.

[192]  K. Uhlig,et al.  Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier , 2012 .

[193]  S. Bangalore,et al.  Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials , 2012, Heart.

[194]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[195]  David C. Wheeler,et al.  Notice , 2012, Kidney International Supplements.

[196]  Giuseppe Mancia,et al.  Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension , 2012, Journal of hypertension.

[197]  J. Feehally,et al.  Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[198]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[199]  R. Webb,et al.  New insights into hypertension-associated erectile dysfunction , 2012, Current opinion in nephrology and hypertension.

[200]  M. Woodward,et al.  Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy: The PROGRESS Trial , 2012, Stroke.

[201]  Reem Mustafa,et al.  A Comprehensive Review of Hypertension in Pregnancy , 2012, Journal of pregnancy.

[202]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[203]  P. Kirchhof,et al.  The task force for the management ofarterial hypertension of the european society ofhypertension (esh) and of the european society of cardiology (esc) , 2013 .

[204]  C. Molina,et al.  Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage , 2013, European journal of neurology.

[205]  M. Woodward,et al.  Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. , 2013, The New England journal of medicine.

[206]  M. Mosteiro,et al.  Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. , 2013, JAMA.

[207]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[208]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[209]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[210]  M. Yang,et al.  The Effects of Calcium Channel Blockers in the Prevention of Stroke in Adults with Hypertension: A Meta-Analysis of Data from 273,543 Participants in 31 Randomized Controlled Trials , 2013, PloS one.

[211]  K. Kario,et al.  Systolic Blood Pressure After Intravenous Antihypertensive Treatment and Clinical Outcomes in Hyperacute Intracerebral Hemorrhage: The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study , 2013, Stroke.

[212]  HiroshiYamagami,et al.  Systolic Blood Pressure After Intravenous Antihypertensive Treatment and Clinical Outcomes in Hyperacute Intracerebral Hemorrhage , 2013 .

[213]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[214]  L. Bortolotto,et al.  Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial. , 2013, Chest.

[215]  R. Conwit,et al.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013, The Lancet.

[216]  D. Wheeler,et al.  Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? , 2013, Kidney international.

[217]  A. Da Silva,et al.  Beta blockers for peripheral arterial disease. , 2013, The Cochrane database of systematic reviews.

[218]  J. Chen,et al.  Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. , 2014, JAMA.

[219]  K. Chien,et al.  Angiotensin Receptor Blockades Effect on Peripheral Muscular and Central Aortic Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials and Systematic Review. , 2014, Acta Cardiologica Sinica.

[220]  A. Alexandrov,et al.  Intensive blood pressure reduction in acute intracerebral hemorrhage , 2014, Neurology.

[221]  E. O’Brien,et al.  Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated With White-Coat and Masked Hypertension in the Population , 2014, Hypertension.

[222]  K. Kario,et al.  Blood Pressure Variability on Antihypertensive Therapy in Acute Intracerebral Hemorrhage: The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study , 2014, Stroke.

[223]  Laura A. Tuttle,et al.  Reproducibility of masked hypertension among adults 30 years or older , 2014, Blood pressure monitoring.

[224]  B. Davis,et al.  Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT , 2014, Journal of General Internal Medicine.

[225]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[226]  M. Tonelli,et al.  Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis , 2015, The Lancet.

[227]  Meilin Liu,et al.  Effects of different types of antihypertensive agents on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of thoracic disease.

[228]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[229]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[230]  G. Breithardt,et al.  Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. , 2016, American heart journal.

[231]  Deepak L. Bhatt,et al.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.

[232]  T. Mansfield,et al.  Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. , 2016, The lancet. Diabetes & endocrinology.

[233]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[234]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials , 2016, Journal of hypertension.

[235]  T. Mansfield,et al.  Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade , 2016, Blood pressure.

[236]  G. Mancia,et al.  Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. , 2016, European Heart Journal.

[237]  A. Scheen.  Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. , 2016, Diabetes research and clinical practice.

[238]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[239]  D. Hanley,et al.  Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. , 2016, The New England journal of medicine.

[240]  K. Sink,et al.  Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. , 2016, American journal of hypertension.

[241]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[242]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[243]  S. Jee,et al.  Association Between Obesity and Chronic Kidney Disease, Defined by Both Glomerular Filtration Rate and Albuminuria, in Korean Adults. , 2017, Metabolic syndrome and related disorders.

[244]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[245]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[246]  M. Cho,et al.  Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure. , 2017, JACC. Heart failure.

[247]  C. Wiysonge,et al.  Beta‐blockers for hypertension , 2017, The Cochrane database of systematic reviews.

[248]  J. Schwartz,et al.  Prevalence of Masked Hypertension Among US Adults With Nonelevated Clinic Blood Pressure , 2017, American journal of epidemiology.

[249]  D. Kansagara,et al.  Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older , 2017, Annals of Internal Medicine.

[250]  William L. Baker,et al.  Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of the ACCORD-BP Trial , 2017 .

[251]  L. Leache,et al.  Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. , 2017, The Cochrane database of systematic reviews.

[252]  J. Park,et al.  Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009–2013) , 2018, PloS one.

[253]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[254]  José R. Banegas,et al.  Relationship between Clinic and Ambulatory Blood‐Pressure Measurements and Mortality , 2018, The New England journal of medicine.

[255]  W. Powers,et al.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2018, Stroke.

[256]  Wilbert S Aronow,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[257]  International Association for the Study of Obesity , 2021, The Grants Register 2022.